Drug Trial Radar · NCT00063999
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,381
Actual
Start
Aug 25, 2003
Primary completion
Jun 29, 2013
Study completion Jan 5, 2021
Sponsor
- Lead sponsor
- GOG FoundationResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 9, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride, cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination chemotherapy regimen is more effective in treating endometrial cancer.
Conditions
- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Stage IVA Uterine Corpus Cancer AJCC v7
- Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
FilgrastimBiological
Given SC
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
PegfilgrastimBiological
Given SC
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Alive at Time of Last Follow-up.Time frame: Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually after for a maximum of 10 years.
Locations
650 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Clearview Cancer Institute
Huntsville, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Providence Hospital
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Mayo Clinic in Arizona
Scottsdale, Arizona
Highlands Oncology Group PA - Fayetteville
Fayetteville, Arkansas
Washington Regional Medical Center - Fayetteville
Fayetteville, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
John Muir Medical Center-Concord Campus
Concord, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente-Fremont
Fremont, California
Saint Jude Medical Center
Fullerton, California
Marin Cancer Care Inc
Greenbrae, California
Long Beach Memorial Medical Center-Todd Cancer Institute
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Community Hospital of Los Gatos
Los Gatos, California
Doctors Medical Center
Modesto, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Oakland
Oakland, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-South Sacramento
Sacramento, California
Kaiser Permanente - Sacramento
Sacramento, California
Salinas Valley Memorial
Salinas, California
University of California San Diego
San Diego, California
Alvarado Hospital Medical Center
San Diego, California
Zuckerberg San Francisco General Hospital
San Francisco, California
Kaiser Permanente-San Francisco
San Francisco, California
UCSF Medical Center-Mount Zion
San Francisco, California
Showing 40 of 650 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.